Epithelioid
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
JTO Clinical and Research Reports 2021 May 18 [Link] Roger Y Kim, Nandita Mitra, Stephen J Bagley, Melina E Marmarelis, Andrew R Haas, Katharine A Rendle, Anil Vachani Abstract Introduction: Since the July 2017 National Comprehensive Cancer Network (NCCN) malignant pleural mesothelioma (MPM) guideline revision recommended second-line immune checkpoint inhibitors (ICIs), studies have suggested a…
Read MoreMalignant peritoneal mesothelioma: correlation between CT imaging features and histologic subtypes
Abdominal Radiology 2021 August 3 [Link] Isha D Atre, Gaurav V Watane, Mukesh G Harisinghani Abstract Purpose: To identify correlation between CT imaging features and histologic subtypes of Malignant Peritoneal Mesothelioma (MPM). Methods: This was a retrospective single-center study of 51 consecutive patients with the diagnosis of Malignant Peritoneal Mesothelioma (MPM). The tumors were classified…
Read MoreSignificance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status
Modern Pathology 2021 September 8 [Link] Julia R Naso, Basile Tessier-Cloutier, Janine Senz, David G Huntsman, Andrew Churg Abstract p53 immunohistochemistry has long been proposed for the separation of benign from malignant mesothelial proliferations, with the older literature suggesting that any degree of positivity supported a diagnosis of mesothelioma. However, using modern immunohistochemistry platforms in…
Read MoreSOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia
The American Journal of Surgical Pathology 2021 August 19 [Link] David B Chapel, Michelle S Hirsch Abstract Primary peritoneal malignant mesothelioma (MM) can demonstrate morphologic overlap with low-grade and high-grade tubo-ovarian serous neoplasms; it is also biologically and prognostically distinct from benign mesothelial proliferations. Currently, there is no single biomarker that can definitively distinguish these…
Read MoreThe use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study
The Lancet. Digital Health. 2021 July 28 [Link] Marjorie G Zauderer, Axel Martin, Jacklynn Egger, Hira Rizvi, Michael Offin, Andreas Rimner, Prasad S Adusumilli, Valerie W Rusch, Mark G Kris, Jennifer L Sauter, Marc Ladanyi, Ronglai Shen Abstract Background: Current risk stratification for patients with malignant pleural mesothelioma based on disease stage and histology is…
Read MoreMalignant pleural mesothelioma showing rare morphology indistinguishable from myxofibrosarcoma concomitant with EGFR-mutated lung adenocarcinoma: A case report
International Journal of Surgical Case Reports 2021 August [Link] Hiroko Onagi, Takuo Hayashi, Tsuyoshi Saito, Satsuki Kishikawa, Kazuya Takamochi, Kenji Suzuki Abstract Introduction and importance: Primary tumors of the pleura are rare, with malignant mesothelioma being the most common of these neoplasms. Pathological diagnosis of sarcomatoid mesothelioma can be more challenging than that of epithelioid…
Read MoreCerebral air embolism after indwelling pleural catheter insertion in a chronic hydropneumothorax secondary to epithelioid mesothelioma
BMJ Case Reports 2021 July 29 [Link] Dissanayake Mudiyanselage Chanaka Jayawardena, Rakesh K Panchal, Sanjay Agrawal, Indrajeet Das Abstract A 75-year-old man with a history of epithelioid mesothelioma and a right-sided indwelling pleural catheter (IPC) presented with a history of a purulent fluid drainage via the IPC. The pleural fluid cultured Klebsiella oxytoca and Enterococcus…
Read MoreComparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma
Lung Cancer 2021 July 17 [Link] Roger Y Kim, Yimei Li, Melina E Marmarelis, Anil Vachani Abstract Objectives: Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinical care is unknown. Our…
Read MoreDiagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study
Pathology Oncology Research 2021 April 9 [Link] Sarah Adel Hakim, Hoda Hassan Abou Gabal Abstract Background: Epithelioid mesothelioma (EM) is the commonest subtype of malignant pleural mesothelioma. Its histopathological discrimination from reactive mesothelial hyperplasia (RMH) could be challenging. Thus, an immunohistochemical panel is mandatory for better discrimination. BAP1 is a newly identified diagnostic marker whose…
Read MoreSquamous differentiation in surgically resected malignant pleural mesothelioma with neoadjuvant chemotherapy
Pathology International 2021 July 13 [Link] Masaya Yotsukura, Noriko Motoi, Akihiko Yoshida, Yukihiro Yoshida, Kazuo Nakagawa, Shun-Ichi Watanabe Abstract We describe a rare case of malignant pleural mesothelioma (MPM) that developed squamous differentiation. MPM can present various patterns of histology, but squamous differentiation has not been reported in any surgically resected cases to date. The…
Read More